In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro
Recently, the pentadecapeptide BPC 157-induced counteraction of bupivacaine cardiotoxicity has been reported. Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsio...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Emergency Medicine International |
| Online Access: | http://dx.doi.org/10.1155/2020/6805354 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555008128712704 |
|---|---|
| author | Marin Lozic Vasilije Stambolija Ivan Krezic Aleksandra Dugandzic Gordana Zivanovic-Posilovic Slaven Gojkovic Josip Kovacevic Luka Vrdoljak Ivan Mirkovic Antonio Kokot Andreja Petrovic Katarina Horvat Pavlov Domagoj Drmic Jelena Suran Alenka Boban Blagaic Sven Seiwerth Predrag Sikiric |
| author_facet | Marin Lozic Vasilije Stambolija Ivan Krezic Aleksandra Dugandzic Gordana Zivanovic-Posilovic Slaven Gojkovic Josip Kovacevic Luka Vrdoljak Ivan Mirkovic Antonio Kokot Andreja Petrovic Katarina Horvat Pavlov Domagoj Drmic Jelena Suran Alenka Boban Blagaic Sven Seiwerth Predrag Sikiric |
| author_sort | Marin Lozic |
| collection | DOAJ |
| description | Recently, the pentadecapeptide BPC 157-induced counteraction of bupivacaine cardiotoxicity has been reported. Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation. BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before. The BPC 157/NO-system relationship was verified with NO-agents, the NOS-blocker L-NAME and the NOS-substrate L-arginine, given alone and/or together, in axillary and spinal intrathecal blocks. BPC 157 applied immediately after lidocaine or 5 min before the application of lidocaine considerably ameliorated plantar presentation. BPC 157 medication considerably counteracted lidocaine-induced limb function failure; L-NAME was counteracted; L-arginine exhibited counteraction when given immediately after lidocaine, but prolongation was seen when given later. Given together, prophylactically or therapeutically, L-NAME and L-arginine (L-NAME + L-arginine) counteracted the other’s response. BPC 157 maintained its original response when given together with L-NAME or L-arginine. When BPC 157 was given together with L-NAME and L-arginine, its original response reappeared. BPC 157 antagonised the lidocaine-induced bradycardia and eliminated tonic-clonic convulsions. Also, BPC 157 counteracted the lidocaine-induced depolarisation of HEK293 cells. Thus, BPC 157 has antidote activity in its own right against lidocaine and local anesthetics. |
| format | Article |
| id | doaj-art-a0b7b5f552e24aefaad33ab6fca255f6 |
| institution | Kabale University |
| issn | 2090-2840 2090-2859 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Emergency Medicine International |
| spelling | doaj-art-a0b7b5f552e24aefaad33ab6fca255f62025-02-03T05:49:52ZengWileyEmergency Medicine International2090-28402090-28592020-01-01202010.1155/2020/68053546805354In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In VitroMarin Lozic0Vasilije Stambolija1Ivan Krezic2Aleksandra Dugandzic3Gordana Zivanovic-Posilovic4Slaven Gojkovic5Josip Kovacevic6Luka Vrdoljak7Ivan Mirkovic8Antonio Kokot9Andreja Petrovic10Katarina Horvat Pavlov11Domagoj Drmic12Jelena Suran13Alenka Boban Blagaic14Sven Seiwerth15Predrag Sikiric16Department of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaDepartment of Pharmacology, School of Medicine, Medical Faculty, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, CroatiaRecently, the pentadecapeptide BPC 157-induced counteraction of bupivacaine cardiotoxicity has been reported. Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation. BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before. The BPC 157/NO-system relationship was verified with NO-agents, the NOS-blocker L-NAME and the NOS-substrate L-arginine, given alone and/or together, in axillary and spinal intrathecal blocks. BPC 157 applied immediately after lidocaine or 5 min before the application of lidocaine considerably ameliorated plantar presentation. BPC 157 medication considerably counteracted lidocaine-induced limb function failure; L-NAME was counteracted; L-arginine exhibited counteraction when given immediately after lidocaine, but prolongation was seen when given later. Given together, prophylactically or therapeutically, L-NAME and L-arginine (L-NAME + L-arginine) counteracted the other’s response. BPC 157 maintained its original response when given together with L-NAME or L-arginine. When BPC 157 was given together with L-NAME and L-arginine, its original response reappeared. BPC 157 antagonised the lidocaine-induced bradycardia and eliminated tonic-clonic convulsions. Also, BPC 157 counteracted the lidocaine-induced depolarisation of HEK293 cells. Thus, BPC 157 has antidote activity in its own right against lidocaine and local anesthetics.http://dx.doi.org/10.1155/2020/6805354 |
| spellingShingle | Marin Lozic Vasilije Stambolija Ivan Krezic Aleksandra Dugandzic Gordana Zivanovic-Posilovic Slaven Gojkovic Josip Kovacevic Luka Vrdoljak Ivan Mirkovic Antonio Kokot Andreja Petrovic Katarina Horvat Pavlov Domagoj Drmic Jelena Suran Alenka Boban Blagaic Sven Seiwerth Predrag Sikiric In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro Emergency Medicine International |
| title | In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro |
| title_full | In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro |
| title_fullStr | In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro |
| title_full_unstemmed | In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro |
| title_short | In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro |
| title_sort | in relation to no system stable pentadecapeptide bpc 157 counteracts lidocaine induced adverse effects in rats and depolarisation in vitro |
| url | http://dx.doi.org/10.1155/2020/6805354 |
| work_keys_str_mv | AT marinlozic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT vasilijestambolija inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT ivankrezic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT aleksandradugandzic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT gordanazivanovicposilovic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT slavengojkovic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT josipkovacevic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT lukavrdoljak inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT ivanmirkovic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT antoniokokot inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT andrejapetrovic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT katarinahorvatpavlov inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT domagojdrmic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT jelenasuran inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT alenkabobanblagaic inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT svenseiwerth inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro AT predragsikiric inrelationtonosystemstablepentadecapeptidebpc157counteractslidocaineinducedadverseeffectsinratsanddepolarisationinvitro |